Do We Still Need Studies on the Value of the TIVAD for Cancer Patients?


I read with interest the article by Singh and colleagues published online December 2013 in the World Journal of Surgery [1]. This prospective, nonrandomized, comparative study was based on the evaluation of the morbidity of chemotherapeutic drugs delivered via a totally implantable venous access device (TIVAD) versus peripheral intravenous access (PIVA… (More)
DOI: 10.1007/s00268-014-2466-6


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics